0000000000228006

AUTHOR

Ferrero C

showing 5 related works from this author

Risultati nazionali delle varietà da malto

2006

I risultati delle prove 2005-2006 nelle 10 località del Centro-sud e Isole hanno evidenziato buone medie produttive con la conferma a leader della varietà Prosa. I buoni risultati in generale evidenziano ulteriormente l’adattabilità di questa specie alle condizioni mediterranee.

confronto varietaleorzo da maltoHordeum vulgare
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

Varietà di orzo da zootecnia, da malto e a seme nudo.

2005

maltosperimentazioneorzo; varietà; malto; sperimentazioneorzovarietà
researchProduct

Orzo da zootecnia: quali varietà scegliere

2006

confronto varietaleHordeum vulgare
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct